YOLFTbeta
Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc

NEUP · NASDAQ · Healthcare / Biotechnology

2.55USD-0.03 (-1.16%)

Price History

Full chart

Market Stats

Previous Close2.58
Open2.63
Day Range2.49 – 2.64
52-Week Range3.19 – 21.40
Volume14.97K
Market Cap19.75M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.06
Dividend Yield0.00%
50-Day Avg3.78
200-Day Avg4.23

About

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Spyridon Papapetropoulos M.D., Ph.D.
  • Employees1
  • Headquarters14 Milliston Road, Millis, MA, United States, 02054, USA
  • Websitehttps://www.neuphoriatx.com

Leadership

  • Dr. Spyridon Papapetropoulos M.D., Ph.D.Interim CEO & Executive Director · b. 1973
  • Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations
  • Mr. Adrian Hinton BEC, F.C.A.Financial Controller · b. 1952
  • Mr. Rajeev Chandra B.Com., C.A., M.B.A.Company Secretary

Financials

Income Statement

Currency: USD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--599.00K907.33K692.83K293.28K293.28K484.09K693.21K1.08M2.91M2.54M3.40M5.35M2.50M18.02M5.08M5.21M27.15M11.94M7.40M32.06K927.54K383.16K0015.65M1.17M
Growth (%)---+51.47%-23.64%-57.67%0.00%+65.06%+43.20%+55.41%+170.48%-12.70%+33.73%+57.14%-53.29%+621.70%-71.79%+2.56%+420.54%-56.00%-38.08%-99.57%+2792.97%-58.69%-100.00%---92.50%
Cost of Revenue-----2.36M2.36M70.63K144.76K213.06K337.62K-868.10K709.91K1.38M17.79M23.45M24.77M24.22M25.38M12.13M-1.69M16.00M671.48K662.99K662.89K662.96K
Gross Profit--599.00K907.33K692.83K-2.07M-2.07M484.09K693.21K1.08M2.91M2.54M3.40M1.15M1.49M9.20M-8.15M5.21M2.84M-13.43M2.68M32.06K-1.27M-9.98M-671.48K-662.99K14.99M511.21K
Gross Margin--100.00%100.00%100.00%-704.28%-704.28%100.00%100.00%100.00%100.00%100.00%100.00%21.56%59.83%51.03%-160.24%100.00%10.44%-112.49%36.22%100.00%-136.74%-2604.39%--95.76%43.54%
Operating Expense--1.77M2.62M3.35M1.23M5.34M6.18M9.30M8.21M11.46M9.95M13.88M13.37M19.76M12.76M12.06M26.89M16.68M7.85M13.43M6.23M7.69M21.04M32.42M26.12M16.12M10.32M
Operating Income-28.70K-540.72K-1.17M-1.71M-2.66M-3.30M-7.40M-5.70M-8.60M-7.13M-8.55M-7.41M-10.48M-12.21M-18.27M-3.56M-20.21M-21.68M-13.84M-21.28M-10.76M-6.19M-8.96M-31.02M-33.09M-26.79M-1.13M-9.81M
Operating Margin---195.33%-188.60%-384.17%-1124.06%-2523.87%-1177.56%-1241.06%-661.69%-293.41%-291.29%-308.11%-228.45%-731.48%-19.77%-397.51%-415.73%-51.00%-178.18%-145.46%-19319.28%-965.74%-8095.19%---7.21%-835.53%
EBITDA-192.92K-818.54K-1.04M-1.68M-2.40M-1.92M-2.89M-8.21M-8.54M-9.23M-7.60M-9.67M-9.78M-7.39M-21.55M6.10M-26.91M-14.16M-3.75M-22.38M-11.21M-1.23M-4.51M-30.25M-31.45M-25.65M-121.90K-9.15M
EBITDA Margin---173.72%-185.14%-345.93%-652.98%-986.46%-1695.66%-1231.84%-856.63%-260.73%-380.09%-287.46%-138.23%-862.94%33.87%-529.31%-271.58%-13.83%-187.42%-151.65%-3833.74%-486.77%-7895.42%---0.78%-779.07%
Net Income-224.96K-847.14K-1.67M-1.96M-3.06M-2.50M-3.53M-4.00M-4.62M-4.58M-5.54M-6.98M-10.00M-3.21M-9.13M3.02M-13.00M-12.40M-5.19M-18.43M-6.77M-4.89M-6.53M-22.94M-32.18M-15.49M-369.63K-13.45M
Net Income Margin---279.37%-216.54%-441.62%-852.13%-1204.34%-827.28%-666.81%-424.86%-190.07%-274.41%-293.94%-60.04%-365.50%16.75%-255.68%-237.84%-19.11%-154.30%-91.57%-15255.18%-704.48%-5986.91%---2.36%-1145.66%
R&D-399.31K1.04M1.85M2.51M2.17M3.40M5.05M5.47M7.29M6.54M7.30M9.72M9.32M14.76M16.74M17.78M18.50M18.61M18.55M6.29M4.00M4.33M23.25M19.67M14.10M9.01M3.55B
R&D as % of Total Revenue--173.72%203.93%362.95%740.80%1159.01%1043.60%789.12%677.12%224.44%286.86%285.77%174.26%590.95%92.91%349.70%354.72%68.57%155.29%85.02%12489.64%466.76%6068.68%--57.54%301952.54%
Interest Expense3.34K2.76K-40.75K203.76K222.10K242.20K244.03K258.72K299.88K228.43K210.64K326.96K65.96K71.36K573.84K662.56K1.41M1.51M1.51M1.66M1.24M1.08M26.87K29.59K---
Interest Expense % of Total Revenue---4.49%29.41%75.73%82.58%50.41%37.32%27.84%7.84%8.28%9.61%1.23%2.86%3.18%13.03%27.13%5.58%12.66%22.39%3860.71%116.12%7.01%----

Balance Sheet

Currency: USD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets142.19K3.17M5.53M8.92M8.47M10.46M13.00M14.63M26.14M27.09M19.95M26.78M36.67M31.83M48.93M61.25M53.02M65.72M64.61M47.80M37.58M23.68M40.77M65.30M19.39M27.65M43.44M28.71B
Total Liabilities506.00K146.83K327.78K3.29M3.95M4.22M4.86M6.51M6.89M6.49M4.87M5.14M6.00M5.32M11.14M19.06M28.51M34.04M33.52M35.34M25.18M14.97M5.01M8.40M4.74M10.16M14.57M4.11B
Total Equity-363.81K3.02M5.20M5.62M4.52M6.24M8.14M8.12M19.25M20.60M15.09M21.64M30.67M26.51M37.79M42.20M24.52M31.69M31.09M12.46M12.39M8.71M35.76M56.91M14.65M17.49M28.87M24.60B
Cash57.41K312.12K724.124.84M4.09M6.08M6.87M3.51M10.87M6.01M3.84M10.72M17.16M17.74M20.49M9.89M20.37M33.94M32.95M18.31M9.79M3.15M21.41M33.56M8.06M12.61M21.59M19.87B
Total Debt166.89K29.85K25.52K2.89M3.43M3.55M3.54M3.25M3.75M3.93M2.98M2.82M3.03M1.20M986.10K1.22M11.33M16.66M14.22M15.85M11.98M8.41M652.04K693.55K582.35K272.74K226.49K34.34K
Net Debt109.48K-282.27K24.79K-1.95M-664.69K-2.53M-3.32M-257.88K-7.13M-2.08M-858.15K-7.90M-14.13M-16.54M-19.50M-8.67M-9.04M-17.28M-18.72M-2.47M2.18M5.26M-20.76M-32.87M-7.80M-12.34M-21.37M-19.87B

Cash Flow

Currency: USD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-105.47K-843.87K-2.61M-2.91M-2.51M-2.98M-3.31M-3.80M-5.83M-5.54M-4.33M-6.92M-7.89M-2.95M-10.44M-12.91M4.94M-15.36M-1.44M-15.02M-10.91M-2.68M-5.66M-21.75M-9.85M-14.68M77.23M-12.35B
Investing Cash Flow---221.40K-864.65K-29.18K-88.89K-2.60M-121.37K-114.50K-359.87K-101.65K-47.87K-69.89K5.85M-1.47M350.73K-296.79K1.10M953.94K59.68K138.42K-134.08K-60.26K621.64K317.41K---
Financing Cash Flow93.46K3.88M4.25M1.83M822.39K4.02M6.35M-266.12K12.32M-193.48K2.68M12.38M12.92M-1.59M17.45M613.07K12.29M33.20M-2.08M1.94M3.05M-3.68M23.71M26.99M5.81M15.11M1.53B17.92B
Capital Expenditure0377.56K221.40K865.34K29.18K149.71K423.00K181.66K124.88K359.87K98.27K44.75K69.90K663.98K191.49K216.60K846.26K196.71K247.51K358.11K69.28K5.29K1.10K1.54K0.25004
Free Cash Flow-105.47K-1.22M-1.55M-2.51M-2.54M-2.24M-3.73M-3.98M-5.95M-5.90M-4.43M-6.96M-7.96M-3.61M-10.63M-13.13M4.09M-15.56M-1.69M-15.38M-10.98M-2.69M-5.67M-21.75M-9.85M-14.68M77.23M-12.35B
FCF to OCF100.00%144.74%59.52%86.01%101.16%74.93%112.79%104.79%102.14%106.49%102.27%100.65%100.89%122.44%101.83%101.70%82.86%101.28%117.19%102.38%100.63%100.20%100.02%100.01%100.00%100.00%100.00%100.00%

Earnings

Report DateDec 1, 2021Feb 23, 2022Jun 1, 2022Aug 25, 2022Nov 30, 2022Feb 23, 2023May 31, 2023Aug 23, 2023Nov 29, 2023Feb 22, 2024May 29, 2024Aug 21, 2024Nov 27, 2024Feb 20, 2025May 20, 2025Sep 29, 2025Nov 14, 2025Feb 17, 2026May 15, 2026Sep 18, 2026Nov 13, 2026
EPS Estimate0.00-0.51-102.60-97.20-0.70-0.66-0.46-0.26-0.59-0.63-0.58-0.66--6.44-3.83-1.31-0.56-0.56-0.56-0.56
EPS Actual-0.81-0.51-102.60-97.20-0.70-0.660.000.000.00-0.64-33.98-0.04-0.00-1.236.55-5.55-4.410.41-0.09-0.13-
Surprise-0.00%0.00%0.00%0.11%-0.64%100.00%100.00%100.00%-1.19%-5758.98%93.39%--1.71%-44.91%-236.64%173.21%83.93%76.79%-
Timing--------------After-hoursAfter-hours-After-hoursPre-marketAfter-hours-

Key Statistics & Ratios

Market Cap19.75M
Enterprise Value82.52K
Trailing P/E0.00
Forward P/E0.00
Price / Sales16.82
Price / Book0.81
EPS-3.06
Book Value5.47
Revenue (TTM)1.17M
Gross Profit (TTM)1.17M
EBITDA-8.35M
Profit Margin0.00%
Operating Margin-15.66%
Return on Equity-61.70%
Return on Assets-19.66%
Shares Outstanding5.41M
Shares Float4.34M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 2 analystsTarget 7.00
  • Buy
    2

Ownership Breakdown

Institutions
61.33%
Insiders
5.02%
Retail / Other
33.65%

Top Institutional Holders

  • Lynx1 Capital Management, LP
    875.33K16.20%
  • AdvisorShares Investments, LLC
    252.91K4.68%
  • Shay Capital LLC
    151.01K2.79%
  • Balyasny Asset Management LLC
    142.18K2.63%
  • Vanguard Capital Management, LLC
    98.52K1.82%
  • Citadel Advisors Llc
    72.56K1.34%
  • Geode Capital Management, LLC
    52.01K0.96%
  • Ikarian Capital, LLC
    47.44K0.88%
  • Vanguard Fiduciary Trust Co
    33.59K0.62%
  • ADAR1 Capital Management LLC
    30.00K0.56%
  • BOOTHBAY FUND MANAGEMENT, LLC
    14.00K0.26%
  • Virtu Financial LLC
    12.03K0.22%
  • Commonwealth Equity Services, LLC
    11.22K0.21%
  • Merck & Co Inc
    10.03K0.19%
  • UBS Group AG
    2.32K0.04%

Top Fund Holders

  • AdvisorShares Psychedelics ETF
    302.79K5.60%
  • Vanguard MStar Total Stk Mkt Idx Invest
    110.17K2.04%
  • Fidelity Extended Market Index
    28.05K0.52%
  • Fidelity Series Total Market Index
    8.04K0.15%
  • Fidelity Nasdaq Composite Index
    2.43K0.04%

Stock Splits

  • Dec 24, 20241:12